株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

医療用マリファナ - 違法から合法へ - 世界市場、競合企業、機会:分析と予測

Medical Marijuana - from Illicit to Legal and Beyond to Pharmaceuticals - Global markets, Competitors and Opportunities: 2015 - 2020 Analysis and Forecasts

発行 Amadee & Company, Inc. 商品コード 324701
出版日 ページ情報 英文 161 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。
Back to Top
医療用マリファナ - 違法から合法へ - 世界市場、競合企業、機会:分析と予測 Medical Marijuana - from Illicit to Legal and Beyond to Pharmaceuticals - Global markets, Competitors and Opportunities: 2015 - 2020 Analysis and Forecasts
出版日: 2015年02月19日 ページ情報: 英文 161 Pages
概要

当レポートでは、世界の医療用マリファナ市場について調査分析し、市場の概要、主要な生産企業、競合環境、大麻の潜在的な役割などについて、体系的な情報を提供しています。

エグゼクティブサマリー

イントロダクション

  • レポートの目的
  • 調査手法と情報源
  • 統計に関する注釈

医療用マリファナ

  • はじめに
  • 何千年も使用
  • 大麻植物
  • 使用の普及率
  • 消費方法
  • その他の薬剤と大麻使用
  • カンナビノイド
  • 内因性カンナビノイドシステム
  • 医療用マリファナのメリット
  • 医療の副作用
  • 大麻の歯への影響
  • 肺への影響
  • 大麻とがん
  • 心血管系への影響
  • 精神への影響
  • 大麻と神経発達への影響
  • 大麻とADHD
  • 大麻依存
  • 大麻の離脱症状
  • 中毒
  • 大麻と精神病

世界の大麻市場

  • 最も広く栽培される違法薬物
  • インディカ vs. サティバ
  • THC vs. CBD
  • 主な大麻製品
  • 法的問題
  • オランダ法
  • 米国法
  • ウルグアイ法
  • 生産量と収穫高が非常に変化
  • 生産量の推計の問題
  • UNDOCの推計
  • 世界の大麻生産量
  • 世界の大麻生産量:地域別
  • 北米の大麻生産量
  • マリファナ市場 vs. OTC鎮痛薬市場
  • カナダのマリファナ市場 vs. 米国市場
  • 合法化と非犯罪化
  • カリフォルニアの医療用マリファナ市場
  • 生産者に有利なカナダ市場の構造
  • 違法マリファナの生産 vs. 医療用マリファナの生産
  • コロラド州はマリファナの闇市場

カナダの医療用マリファナ市場

  • 新興の成長産業
  • カナダの医療用マリファナの近代史
  • MMAR vs. MMPR
  • MMARが見直された理由
  • MMPRの目的
  • 医療用マリファナの規制
  • 差し止め命令
  • 患者用の合理化
  • MMPRによる処方プロセス
  • 出荷/梱包要件
  • MMPRによるライセンスプロセス、他

企業プロファイル

図表

目次

The objective of this report is to provide a detailed analysis of the global market for Medical Marijuana. It is also to provide a comprehensive analysis of the leading companies producing these products, as well as the competitive environment they operate in. Marijuana (cannabis) remains a controversial drug in the twenty-first century. However, the potential role of specific cannabinoids for medical benefits will be revealed as the twenty-first century matures.

Marijuana is the most widely cultivated illicit drug plant worldwide. The international legal framework on drug control is provided by three United Nations Conventions, which instruct countries to limit drug supply and use to medical and scientific purposes. Nevertheless, there continues to be increasing debate over decriminalization, or even legalization of cannabis in particular.

This report provides an estimate of global cannabis production both in volume and value during the 2015-2020 period. The illicit use of marijuana dwarfs the medical use and that probably always will be the case. But to put global cannabis production in perspective, it is bigger than retail sales of all OTC (over-the-counter) analgesic pharmaceuticals by a factor of 9 and sales of pain medication pharmaceuticals by a factor of 25.

23 U.S. states and the District of Columbia now have legalized medical marijuana, and two states (Colorado and Washington state) allow for adult use (commonly referred to as recreational use). However, the focus in this report is on the Canada medical marijuana market, which is a new, emerging growth industry. The medical marijuana space in Canada, which went into effect in April 2014, has created conditions for a new highly regulated commercial industry with a limited amount of suppliers vetted extensively by Health Canada. Over $100 million in investment dollars have flowed into the Canadian medical marijuana industry already.

The future of medical marijuana lies in pharmaceutical products for the management of neuropathic pain, hypertension, post-stroke neuroprotection, multiple sclerosis, epilepsy, cancer, and other disorders.

Table of Contents

CONTENTS

EXECUTIVE SUMMARY

INTRODUCTION

  • Report Objectives
  • Methodology and Sources
  • Statistical Notes

MEDICAL MARIJUANA

  • Introduction
  • Used for Thousands of Years
  • Cannabis Sativa Plant
  • Prevalence of Use
  • Method of Consumption
  • Cannabis Use with Other Drugs
  • Cannabinoids
  • Endocannabinoid System
  • Benefits of Medical Marijuana
  • Medical Adverse Effects
  • Dental Effects of Cannabis
  • Pulmonary Effects
  • Cannabis and Cancer
  • Cardiovascular Effects
  • Psychiatric Adverse Effects
  • Cannabis and Neurodevelopment Effects
  • Cannabis and ADHD
  • Cannabis Dependence
  • Cannabis Withdrawal Syndrome
  • Addiction
  • Cannabis and Psychosis

GLOBAL CANNABIS MARKET

  • Most Widely Cultivated Illicit Drug Plant
  • Indica vs. Sativa
  • THC vs. CBD
  • Main Cannabis Products
  • Legal Issues
  • Netherlands Laws
  • United States Laws
  • Uruguay Laws
  • Production and Yields Highly Variable
  • Production Estimation Issues
  • UNDOC Estimates
  • Global Cannabis Production
  • Global Cannabis Production by Region
  • North America Cannabis Production
  • Marijuana Market vs. OTC Analgesic and Pain Pharmaceuticals Markets
  • Canada Marijuana Market vs. U.S. Market
  • Legalization and Decriminalization
  • California Medical Marijuana Market
  • Canadian Market Structure More Favorable for Producers
  • Illicit Marijuana Production vs. Medical Marijuana Production
  • Colorado Black Market for Marijuana

CANADA MEDICAL MARIJUANA MARKET

  • New Emerging Growth Industry
  • Modern History of Medical Marijuana in Canada
  • MMAR vs. MMPR - Regulatory Overhaul Following Safety Concerns and Abuse
  • Why MMAR Was Overhauled
  • Objectives of MMPR
  • Marihuana for Medical Purposes Regulations - The New System
  • Injunction Explained
  • Patient Application Streamlined
  • Prescription Process Under MMPR
  • Shipping/Packaging Requirements
  • Licensing Process Under MMPR
  • Growing Enrollment Numbers Points to Strong Growth
  • Health Canada Projected Demand
  • How HC Made Its Forecasts Is Somewhat Unknown
  • Canada Forecast Patient Growth
  • U.S. Forecast Patient Growth
  • Growth Rates from A Low Base.
  • Market in 2024
  • Proposed Expansion Plans of LPs May Satisfy Demand
  • More than C$100 Million Invested
  • Product Pricing Varies by LP
  • Compassionate Pricing Is Not Mandatory
  • Licensed Producers
  • Good To Be an LP
  • Physician Role Is Very Important
  • Physician Role Should Not Be Overstated
  • MMAR Physician Authorizations
  • Physician Penetration Under MMPR
  • Health Canada View on Medical Marijuana
  • College of Family Physicians of Canada Prescribing Guidelines
  • Patients Using Medical Marijuana in Canada by Ailment
  • Soils vs. Hydroponic
  • Indoor vs. Outdoor
  • Production Cycle
  • Cost of Production
  • Infused Products Not Allowed Yet
  • Industry Catalysts
  • Consolidation More Likely Than Acquisition
  • Edibles Legalization
  • Edibles Issues
  • Insurance Coverage
  • Recreational Legalization
  • Potential Risks
  • Legislation Changes
  • Enterprise Valuations
  • Adoption Rates Still Uncertain
  • Product Quality and Public Perception

COMPANY PROFILES

Aphria Inc

  • (Company Overview, Medical Marijuana)

Bedrocan Cannabis Corp.

  • (Company Overview, Strategy, Medical Marijuana, Competitive Advantages, Bedrocan BV, Advantages to Bedrocan BV Partnership, License Agreement Lowers Risk, License Agreement Provides Upside, South American Countries Looking to Legalize, Bedrocan Product Suite, Bedrocan, Bedropuur, Bedica, Bediol, Small Product Suite, CFPC Preliminary Guidelines, Facilities, Import Facility, Domestic Production Facility, Acquisition for Facility Growth, BV Import Schedule, State of the Art Growing Operations, Production Flow, Production Ramp, Annual Sales Volume, Cost Per Gram, Marketing Strategy, Retail Prices, Patient Sign up Process, Current Patient Composition, Wait List, Patient Count Growing, Patient Consumption Rates, Physician Outreach and Medical Advisory Board, ISO-9000 Certified, Standardization Advantages, Management and Directors Bring Relationships, Experience, Private Placement, Enterprise Value, Financials)

Cannabis Science, Inc.

  • (Company Overview, Medical Marijuana, Key Indications, Key Target-Based Actions, Key Technologies, Drugs, CT-1, CS-TATI-1, Cannabinoid Compounds, Facilities, Collaborations, Acquisitions and Spin-Offs, Licensing Agreements, R&D, Financials)

GW Pharmaceuticals plc

  • (Company Overview, Medical Marijuana, Sativex Multiple Sclerosis Market, Sativex Cancer Pain Market, Epilepsy, Epidiolex Market, Inflammatory Bowel Disease, Marijuana Use and IBD, Cannabinoid Receptor System and Immune Regulation, Ulcerative Colitis Background, Ulcerative Colitis Subtypes, Goal of Ulcerative Colitis Treatment, Ulcerative Colitis Market, Trials, Financials)

Mettrum Health Corp

  • (Company Overview, Medical Marijuana, Facilities, Production, Bowmanville Facility, Creemore Facility, Monetizing Product Through Bowmanville, 500 kg License, Licensing No Longer A Constraint, Resuming Customer Acquisition, Market Strategy, RTO And Private Placement, Profits Could Reach C$50 Million, Barriers To Entry Growing, Oilseed Works Purchase, Financials)

OrganiGram Holdings Inc.

  • (Company Overview, Medical Marijuana, Facilities, Capacity, Products, Marketing, Patients, Trauma Healing Centers Agreement, Financials)

Tweed Marijuana Inc.

  • (Company Overview, Initial Financing, Medical Marijuana, Facilities, Smiths Falls Facility, Security, Growing Equipment, Laboratory, Expansion Plans, Smith Falls Grow Operations, Smiths Falls Capacity to Double, Mother Room Houses ~5,000 Plants, Smiths Falls Could Produce ~7,500 - 10,000 kg/Year, Tweed Farms, Tweed Farms Property, Tweed Farms Grow Operations, 70% Lower Costs, Capacity Estimated at ~2,900-3,700 kg Annually, Factors Offsetting Benefits of Greenhouse Production, Product Offerings, Pricing, Vaporizers, Radiation, Other Potential Revenue Streams, Sales and Marketing Strategy, Direct-to-Consumer Sales Process, Go-to-Market Strategy, Patient Acquisition, Medical Advisory Board, Canadian AIDS Society, Trade Events, Ownership, Financials)

TABLES

  • 1. Lifetime Use of Marijuana by Country: 2007
  • 2. Types of Cannabinoids
  • 3. Potential Benefits of Cannabis Based on Research Studies
  • 4. Potential Adverse Effects of Marijuana
  • 5. DSM-IV-TR Cannabis Use and Induced Disorders
  • 6. Worldwide Number (Millions) and Prevalence (%) of Users by Type of Illicit Drug: 2012
  • 7. Comparison of Marijuana Laws in the Netherlands, Colorado State, Washington State, Uruguay
  • 8. World Cannabis Herb and Resin Production (Hectares, Metric Tons): 2003-2008
  • 9. Global Cannabis Production Volume (MT), Value (USD) and Average Selling Price (Million USD/MT): 2015-2020
  • 10. Global Cannabis Production Volume by Region (Metric Tons): 2015
  • 11. North America Cannabis Production Volume (MT), Value (USD) and Average Selling Price (Million USD/MT): 2015
  • 12. Global Sales of Over-the-Counter (OTC) Pharmaceuticals by Application (USD Million): 2013
  • 13. California Medical Marijuana Market Highlights
  • 14. Canada Licensed Producer Production by Company (kg): 2014-2018
  • 15. Therapeutic Uses Of Cannabis
  • 16. History of Canada Medical Marijuana Regulations: 1996-2014
  • 17. Key Differences Between MMAR and MMPR
  • 18. Sample MMPR Application Form
  • 19. Canada Medical Marijuana Market in 2024 Using Different Patient Number and Price Assumptions (Number, 2014 C$ /Gram)
  • 20. Canada Public LPs Expected Production Capacity (kg): 2015
  • 21. 15 Current Health Canada Licensed Producers (Location, Description, Capacity, Patients): 1Q 2015
  • 22. Aphria Product Offerings
  • 23. Bedrocan Operations Timeline: 2012-2015
  • 24. Bedrocan Cannabis Corp. Import Facility Features
  • 25. Bedrocan Cannabis Corp. Domestic Facility Features
  • 26. Bedrocan Cannabis Registration Application Form
  • 27. Bedrocan Cannabis Corp. Income Statement: 2015-2019
  • 28. Cannabis Science, Inc. Income Statement: 2012-2014
  • 29. Sativex Multiple Sclerosis Revenue Model : 2013-2027
  • 30. Sativex Cancer Pain Revenue Model: 2013-2027
  • 31. Tuberous Sclerosis Complex Case Studies Show Compelling CBD Benefits in Highly Refractory Epilepsy Patients
  • 32. Epidiolex Revenue Model: 2013-2028
  • 33. Published Research Citing the Clinical Potential of Cannabis in Inflammatory Bowel Disease
  • 34. Inflammatory Bowel Disease by Type, Endocannabinoid Changes and Receptor Changes
  • 35. The Five Types of UC: Variability in Acute Presentation and Long Term Outcomes
  • 36. GW Pharmaceutical Trials: 2014-2015
  • 37. GW Pharmaceuticals Income Statement (GBP Million): 2011-2017
  • 38. Mettrum Spectrum Products
  • 39. Mettrum Spectrum Use of Private Placement Proceeds
  • 40. Mettrum Health Corp. Income Statement: 2014-2019
  • 41. OrganiGram Current Product Offerings
  • 42. OrganiGram Future Product Offerings
  • 43. Smiths Falls Estimated Production Breakdown (kg)
  • 44. Tweed Farms Estimated Production Breakdown (kg)
  • 45. Factors Offsetting Benefits of Greenhouse Production
  • 46. Tweed Products and Prices
  • 47. Tweed Marijuana Inc. Income Statement: 2014-2016

FIGURES

  • 1. Indica and Sativa Cannabis Plants
  • 2. Global Pain Management Pharmaceuticals Revenue by Company (USD Billion, %): 2013
  • 3. Number of U.S. States Legalizing Medical Marijuana over Time: 1996-2014
  • 4. Patients by Classification Under Canada Marihuana Medical Access Regulations (Number, %): 2013
  • 5. 15 g and 5 g Containers with Product Type and CBD/THC Content by Weight %
  • 6. Canada Marihuana for Medical Purposes Regulations Patients and Growth Rate (Number, %): 2014-2034
  • 7. U.S. Medical Marijuana Population by State and Respective Penetration Rates (Number, %)
  • 8. Average Price Per Gram and Number of Strains for Selected LPs: 2014
  • 9. Number of Canada Physicians by Type and Province Prescribing Medical Marijuana: 2014
  • 10. Survey of Patients Using Medical Marijuana in Canada by Ailment: 2014
  • 11. Medical Marijuana Production Cycle by Time and Activity
  • 12. Long Run Average Cost of Cannabis Production (C$/Gram)
  • 13. THC Oil/Kif Butter/Medical Marijuana Infused Peanut Butter
  • 14. Public LP Enterprise Value Range: January 2015
  • 15. Bedrocan
  • 16. Bedropuur
  • 17. Bedica
  • 18. Bediol
  • 19. Bedrolite
  • 20. Canadian LP Pricing and Strain Offerings by Company (C$/Gram, Number Strains): 2014
  • 21. Ulcertative Colitis Schematic
  • 22. Aerial View of Tweed's Smiths Falls Facility
  • 23. Smiths Falls Production Facility Layout
  • 24. Evolution of Smiths Falls' Installed Capacity: 2014-2016
  • 25. Smiths Falls' Mother Room and Cuttings
  • 26. Ariel View of Tweed Farms Production Facility
  • 27. Marijuana Vaporizers
  • 28. Selection of Tweed's Strains Produced at Smiths Falls
Back to Top